Fast Market Research

Multiple Sclerosis - Pipeline Review, H2 2016: New Research Report Available at Fast Market Research

Fast Market Research announces the availability of the new Global Markets Direct report, "Multiple Sclerosis - Pipeline Review, H2 2016", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 02/10/2017 -- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H2 2016, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.

Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Get More Details on this Report and a Full Table of Contents at Multiple Sclerosis - Pipeline Review, H2 2016

The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 9, 30, 32, 173, 36 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 46 and 2 molecules, respectively.

Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).

-The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)

Reasons to Get this Report

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Companies Mentioned in this Report: 2-BBB Medicines BV, 4D Pharma Plc, AB Science SA, AbbVie Inc, Abion Inc, Ablynx NV, Abzena Plc, Acorda Therapeutics Inc, Actelion Ltd, Adamas Pharmaceuticals Inc, Addex Therapeutics Ltd, Adhaere Pharmaceuticals Inc, Aegis Therapeutics LLC, Affectis Pharmaceuticals AG, AiCuris GmbH & Co KG, Alkermes Plc, Alpha Cancer Technologies Inc, Amarna Therapeutics BV, Anavex Life Sciences Corp, Antisense Therapeutics Ltd, Aphios Corp, Apitope International NV, ARA Healthcare Pvt Ltd, Arena Pharmaceuticals Inc, arGEN-X BV, Argos Therapeutics Inc, Arrien Pharmaceuticals LLC, Artielle ImmunoTherapeutics Inc, Astellas Pharma Inc, Asterias Biotherapeutics Inc, Atara Biotherapeutics Inc, Athersys Inc, Atlantic Bio Sci LLC, Axxam SpA, Baliopharm AG, Bio-Cancer Treatment International Ltd, BioAegis Therapeutics Inc, BioApex sro, Biocad, Biocon Ltd, Biogen Inc, Biogenomics Ltd, BioHealthonomics Inc, Biokine Therapeutics Ltd, Biomar Microbial Technologies, Bioncotech Therapeutics SL, Bionovis SA, Bionure Farma SL, Biovista Inc, Bolder Biotechnology Inc, BrainStorm Cell Therapeutics Inc, Bristol-Myers Squibb Company, C4X Discovery Holdings PLC, CASI Pharmaceuticals Inc, Catalyst Pharmaceuticals Inc, Celgene Corp, Cell Cure Neurosciences Ltd, Cell2B Advanced Therapeutics SA, Cellceutix Corp, Cognosci Inc, Coherus BioSciences Inc, Commence Bio Inc, Compugen Ltd, Connexios Life Sciences Pvt Ltd, Critical Outcome Technologies Inc, CuraVac Inc, Cyxone AB, Daiichi Sankyo Company Ltd, Dimerix Bioscience Pty Ltd, Dong-A Socio Holdings Co Ltd, Eisai Co Ltd, Eli Lilly and Company, Endece LLC, Evgen Pharma Plc, Evotec AG, F. Hoffmann-La Roche Ltd, Flex Pharma Inc, Forward Pharma A/S, FPRT Bio Inc, Gemac SA, Genervon Biopharmaceuticals LLC, GeNeuro SA, Genzyme Corp, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Glialogix Inc, Hansa Medical AB, Harbor Therapeutics Inc, HitGen LTD, Humabs BioMed SA, Hutchison MediPharma Ltd, Iltoo Pharma, Immune Response BioPharma Inc, Immune Therapeutics Inc, ImmuNext Inc, Immungenetics AG, Inception Sciences Inc, Innate Immunotherapeutics Ltd, Inovio Pharmaceuticals Inc, Io Therapeutics Inc, Jyant Technologies Inc, Kadimastem Ltd, Kadmon Corp LLC, KAHR medical Ltd, KaloBios Pharmaceuticals Inc, Kancera AB, Kareus Therapeutics SA, Karo Pharma AB, Karyopharm Therapeutics Inc, Kissei Pharmaceutical Co Ltd, KPI Therapeutics Inc, Kyorin Pharmaceutical Co Ltd, Lead Discovery Center GmbH, LFB SA, Lipocure Ltd, MacroGenics Inc, MAKScientific LLC, Mapi Pharma Ltd, Marathon Pharmaceuticals LLC, MedAnnex Ltd, MedDay SA, Medestea Research & Production SpA, MedImmune LLC, Merck KGaA, Meta-IQ ApS, Mitochon Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corp, MorphoSys AG, Mount Tam Biotechnologies Inc, Neuralstem Inc, Neuren Pharmaceuticals Ltd, Neuronax SAS, Neurotec Pharma SL, New World Laboratories Inc, Novartis AG, NovImmune SA, Nuevolution AB, Ogeda SA, Omeros Corp, OncoImmune Inc, Opexa Therapeutics Inc, Oryzon Genomics SA, OSE Immunotherapeutics, Parvus Therapeutics Inc, Peptinov SAS, Pfenex Inc, Pfizer Inc, PharmaEssentia Corp, PharmatrophiX Inc, Pharmaxis Ltd, Pieris Pharmaceuticals Inc, Polleo Pharma Ltd, ProNoxis AB, Prothena Corp Plc, Q Therapeutics Inc, ReceptoPharm Inc, RedHill Biopharma Ltd, RegeneRx Biopharmaceuticals Inc, Regenesance BV, Renovo Neural Inc, Resverlogix Corp, ReveraGen BioPharma Inc, Rigel Pharmaceuticals Inc, Rodos BioTarget GmbH, SanBio Inc, Santhera Pharmaceuticals Holding AG, Sareum Holdings Plc, Sorrento Therapeutics Inc, Symic Biomedical Inc, Synthon Holdings BV, Targazyme Inc, Teikoku Pharma USA Inc, Teva Pharmaceutical Industries Ltd, Therapix Biosciences Ltd, TikoMed AB, Toleranzia AB, Topas Therapeutics GmbH, TxCell SA, Vaccinex Inc, Vakzine Projekt Management GmbH, Virogenomics BioDevelopment Inc, Vitae Pharmaceuticals Inc, VivaCell Biotechnology Espana SL, Xenetic Biosciences (UK) Ltd, XL-protein GmbH, Yungjin Pharm Co Ltd, Zenith Capital Corp, Zydus Cadila Healthcare Ltd

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016
-Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2016
-Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016
-Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016
-Multiple Sclerosis - Pipeline Review, H1 2016